Support: 888-992-3836 Home NewsWire Subscriptions ...Apr 8, 2022 · The Ninth Circuit panel held that defendant was not required to disgorge to CytoDyn his short-swing profits from exercising options and warrants granted by CytoDyn, entitling him to purchase and later sell CytoDyn shares. The panel held that the short-swing transaction fell within an exemption, set forth in SEC Rule 16b-3(d)(1) because the option and warrant award was “approved by the board ... The feline has attacked CytoDyn Inc. (OTCMKTS: CYDY) nine times within the last 8 months in an attempt to discredit the company as CYDY shares have risen from $0.29 in December 2019 to a transient 52 week high of over $10. Feuerstein, however, cannot seem to admit he has been totally off-base for the greater portion of a year.Jul 27, 2021. CytoDyn, which has been fending off lawsuits from directors and shareholders for more than a year, now faces a new challenge from an investor group that is trying to remake the board ...Jun 29, 2020 · Support: 888-992-3836 Home NewsWire Subscriptions ... Track CytoDyn Inc (CYDY) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsCytoDyn's stockholders have been informed that a meeting will be held on October 28.19 All steps necessary to conduct that meeting have been taken. Cancelling it a week before it is to go forward would result in substantial costs and serious confusion. 9. Factor (iv) of Kirpat asks the Court to determine whether the public interest will be ...Get the latest CytoDyn Inc (296.SG) stock news and headlines to help you in your trading and investing decisions. ... Stuttgart - Stuttgart Delayed Price. Currency in EUR. Follow. 0.1800 +0.0090 ... CytoDyn is in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, to be used as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV. The CCR5 receptor is a protein located on the surface of various cells including white blood cells, stellate cells which produce scar tissue in ...Coronavirus disease 2019 (COVID-19) is associated with considerable morbidity and mortality. The number of confirmed cases of infection with SARS-CoV-2, the virus causing COVID-19 continues to escalate with over 70 million confirmed cases and over 1.6 million confirmed deaths. Severe-to-critical COV …Show search box Hide search box Menu Finder tools Tools InvestingOct 7, 2021 · Nader Pourhassan, Ph.D., CytoDyn’s President and Chief Executive Officer, commented, “We are aggressively pursuing these legal actions against Amarex. We believe their numerous failures have ... A federal grand jury has returned an indictment charging Nader Pourhassan, age 59 of Lake Oswego, Oregon, and Kazem Kazempour, age 69, of Potomac Maryland, for their roles in schemes to defraud investors in CytoDyn Inc., a publicly traded biotechnology company based in Vancouver, Washington. Pourhassan was CytoDyn’s president and …CytoDyn's stock falls 4% after getting warning letter from FDA about experimental COVID-19 treatment. Shares of CytoDyn Inc. CYDY, -4.11% fell 4.9% in trading on Tuesday, the same day that the Food and Drug Administration issued a warning letter to the company over a video that features the former CEO... 1 year ago - Market Watch.CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications using leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.Abstract. Integrin alpha L (ITGAL) is a member of the integrin family in which the abnormal expression is linked with carcinogenesis and immune regulation. However, the relation between ITGAL and the prognosis of gastric cancer (GC) and tumor-infiltrating lymphocytes (TILs) are not well understood. The differential expressions of ITGAL in …CytoDyn completed its Phase 2 clinical trial (CD10) for COVID-19, a double-blinded, randomized clinical trial for mild-to-moderate patients in the U.S. which produced statistically significant ...... Cytodyn Operations Inc. USA, CYDY, OTHER OTC Market. 132418851, Nuo Therapeutics ... STUTTGART. 203643101, 11087681 Canada Inc. CANADA, VOTI.H, TSX VENTURE ...CYDY CytoDyn Inc: Stuttgart link https://www.bloomberg.com/quote/296:GR - #5845085CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More ..."In the meantime, Pourhassan allegedly sold approximately $15.8 million worth of CytoDyn stock based on the false information, netting profits of more than $4.7 million," the Securities and ...CytoDyn Inc (CYDY) Message Board. Stuttgart Exchange opens in about 10 hours. 2am ES. Message Board: Public ... (Total Views: 2261) Posted On: 03/29/2020 3:47:50 PM. Posted By: Rex47. Stuttgart Exchange opens in about 10 hours. 2am EST or 11pm PST. Volume has been under 100K shares normally with 347K traded on Friday. …CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV ...Cytodyn has raised a total of. $89.5M. in funding over 12 rounds. Their latest funding was raised on Sep 15, 2021 from a Post-IPO Equity round. Cytodyn is registered under the ticker OTCQB:CYDY .CytoDyn is currently enrolling patients in two clinical trials for COVID-19, a Phase 2 randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and a Phase 2b/3 randomized ...Cytodyn Inc + Add to watchlist 296:STU Actions Price (EUR) 0.172 Today's Change 0.001 / 0.58% Shares traded 0.00 1 Year change -62.45% Beta -- Data delayed at least 15 minutes, as of Sep 22 2023....Gilead Sciences (NASDAQ: NASDAQ: GILD ), with its $90 billion market capitalization, is a massive player in the anti-viral business. Specifically, in HIV, the company has played an enormous part ...CytoDyn | 2,826 followers on LinkedIn. CytoDyn’s purpose is to help enhance the lives of patients with life-threatening diseases. | CytoDyn is in late-stage clinical development of leronlimab, a ...CytoDyn () has executed an exclusive supply and distribution agreement with Macleods Pharmaceuticals in India.; This commercial agreement will enable Macleods to sell leronlimab in India following ...CytoDyn is pleased to show strong data for critically ill COVID-19 patients. Considering the fact that: (1) A higher proportion of patients over 65 were enrolled in the leronlimab arm (33% ...CytoDyn is also conducting a Phase 2 clinical trial with leronlimab in mTNBC, a Phase 2 basket trial in solid tumor cancers (22 different cancer indications), Phase 2 investigative trial for post ...Cytodyn. Find out what works well at Cytodyn from the people who know best. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Compare pay for popular roles and read about the team’s work-life balance. Uncover why Cytodyn is the best company for you.الاتحاد الدولي للصحافة العربية، منظمة دولية مستقلة "غير حكومية" لا تتبع لأي دولة أو حكومة أو حزب أو تيار سياسي أو ديني أو عرقي، مسجلة في المملكة المتحدة تحت رقم 9599569 بتاريخ 19/5/2015 م , وتصديق السفارة المصرية بلندن فى 28 مايو ...Mountainman5: STUTTGART/GERMANY PLUS 6,76 %!!!!! Support: 888-992-3836 Home NewsWire SubscriptionsCytoDyn Inc (CYDY) Stock Research Links. CYDY Message Board Company Profile Time & Sales; Recent News Filings Financials Buy RatingCytodyn ( OTCQB:CYDY) recently reported data from their NASH and triple-negative breast cancer studies using Leronlimab. The data revealed impressive results in both indications which will improve ...CytoDyn has already completed a Phase 2 and Phase 3 trial for mild-to-moderate and severe-to-critical COVID-19 patients, respectively, for which CytoDyn did not meet its primary or secondary ...Offers valid only for new residential customers or previous customers with account in good standing who have not had our service within the last 60 days. All names, logos, images and service marks are property of their respective owners. Other restrictions may apply. Access helpful guides and support on internet, TV, phone, TiVo, account, and ...Clean Vision Corp $0.051 CLNV16.07% RELIEF THERAPEUTICS Holding SA $2.35 RLFTF2.40% Market newsCytodyn isn't any of those -- but happens to have a promising drug so the high optimism. Stock promoters attract stock shorts and OTC environment allows all kinds of hype. High risk environment ...About CytoDyn CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications using leronlimab, a novel humanized monoclonal antibody targeting ...Jul 24, 2023 · CytoDyn is seeking $100 million in damages on grounds that Amarex failed to perform work to a professional standard and billed for services it didn’t carry out. Migliarese said CytoDyn has ... CytoDyn seems to be dead in the waters. In my view, it is tough to assess leronlimab scientifically because the data they have generated is suspect. The FDA has told them, twice in the last 12 ...Management will provide approximately 90 minutes to address questions submitted online by analysts and investors. Date: Monday, March 8, 2021. Time: 1:00 pm PT / 4:00 pm ET. Dial-In: None ...CytoDyn, Inc. is a drug manufacturing firm specializing in new, novel forms of AIDS and HIV treatment drugs. The company is best known for Cytolin, a drug that represents major advances in the treatment of HIV/AIDS. Cytolin offers an alternative by using the immune systems of those suffering from HIV/AIDS, in contrast to using antiretroviral ...CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More ...CytoDyn Announces Company Updates and Investment Community Update Webcast. Jul 11, 2023 4:05pm EDT. CytoDyn Announces President Takes Medical Leave of Absence. May 24, 2023 5:05pm EDT. View All News. Upcoming Events View IR Calendar. Annual Meeting of StockholdersStock analysis for CytoDyn Inc (296:Stuttgart) including stock price, stock chart, company news, key statistics, fundamentals and company profile.CytoDyn Inc announced positive preliminary results from the 20-patient-cohort who have completed the open-label portion of the Phase 2 trial for nonalcoholic steatohepatitis (NASH). The Vancouver-based company's current Phase 2 NASH trial is designed to test in 90 patients whether leronlimab may inhibit the devastating liver fibrosis ...CytoDyn expects to refile its BLA in the first half of calendar year 2021. CytoDyn has completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected ...On May 17, 2021, following public communications by CytoDyn regarding differences in small subgroups in one of the clinical trials CytoDyn conducted with leronlimab for the treatment of patients ...CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV ... CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More ...Overview OPEN 0.18 PREV. CLOSE 0.18 VOLUME 271,620.00 MARKET CAP 161.056M DAY RANGE 0.17 - 0.18 52 WEEK RANGE 0.15 - 0.48purchased or otherwise acquired the common stock of CytoDyn Inc. (“CytoDyn” or the “Company”) between March 27, 2020 and May 17, 2021 (the “Class Period”), and were damaged thereby (the “Class”), allege the following upon information and belief, except as toCytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to ...Sep 10, 2021 · An interim analysis will be conducted 28 days following enrollment of 245 patients (40% of targeted trial patients) VANCOUVER, Washington, Sept. 09, 2021... OPDP’s warning letter to CytoDyn, Inc. (CytoDyn) states that a video interview made available via hyperlink on CytoDyn’s corporate website misbrands leronlimab, an investigational new drug for the treatment of COVID-19, by representing the drug as safe and effective for the purpose for which it is being investigated. The warning …4 thg 2, 2019 ... ... Stuttgart, Allmandring 31, D-70569 Stuttgart, Germany. Find articles ... and is CMO and Board member of CytoDyn. RGP holds ownership interests ...CytoDyn () has executed an exclusive supply and distribution agreement with Macleods Pharmaceuticals in India.; This commercial agreement will enable Macleods to sell leronlimab in India following ...CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play…CytoDyn CEO Nader Pourhassan is a relentless promoter of what he believes will be a game-changing therapy for HIV, cancer, Covid and more. A chorus of critics and two lawsuits stand in his way.... Cytodyn Operations Inc. USA, CYDY, OTHER OTC Market. 132418851, Nuo Therapeutics ... STUTTGART. 203643101, 11087681 Canada Inc. CANADA, VOTI.H, TSX VENTURE ...CytoDyn seems to be dead in the waters. In my view, it is tough to assess leronlimab scientifically because the data they have generated is suspect. The FDA has told them, twice in the last 12 ...CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More ...CytoDyn's ill-fated BLA appears to have hit a roadblock. CytoDyn's BLA for leronlimab in treatment of HIV as a combination therapy has been teased as imminently fileable at least since the ...CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Mar 5, 2021 · CytoDyn expects to refile its BLA in the first half of calendar year 2021. CytoDyn has completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected ... Apr 5, 2023 · VANCOUVER, Washington, April 05, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the ... CytoDyn Inc. CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab combined with standard antiretroviral therapies in HIV ...CytoDyn Inc. reported that it has treated the first patient in its Phase 2 basket trial for 22 solid cancer tumors. The trial deals with a wide range of cancers and tumors such as throat, stomach ...Cytodyn Inc (CYDY:QBB) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more.CytoDyn has already completed a Phase 2 and Phase 3 trial for mild-to-moderate and severe-to-critical COVID-19 patients, respectively, for which CytoDyn did not meet its primary or secondary ...CytoDyn completed enrollment of 390 patients in its Phase 2b/3 randomized clinical trial for the severe-to-critically ill COVID-19 population and expects to release results in mid-January 2021 ...VANCOUVER, Washington, April 05, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the ...Support: 888-992-3836 Home NewsWire Subscriptions ...Back on January 6th, Samsung sent CytoDyn a written notice that they had breached its agreements by failing to pay roughly $13.5M due by the year-end of 2021. An additional $22.8M was due on ...CytoDyn Inc (CYDY) Stock Price Today, Quote, Latest Discussions, Interactive Chart and News. Advertisement. 3rd Party Ad. Not an offer or recommendation by Stocktwits. See …CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5.1 AND 2 Bedroom Apartments for Rent!! 2 Bed 1 Bath Apartment For Rent! 1/1, 2/1 and 2/2 Apartments For Rent!! $2,700 - 2BR/ 2BA Beach Cottage SOUTH of 30A! Beach walkout! First floor/corner unit, 30 steps to private beach! Water Included- $1955 a month- 2 Months Free!!! 1 bedroom apartment with everything included!Pourhassan was CytoDyn’s president and CEO at the time of the alleged fraud. Kazempour is the co-founder, president, and CEO of Amarex Clinical Research LLC (Amarex), a private company with offices in Germantown, Maryland, that managed CytoDyn’s clinical trials, and was CytoDyn’s regulatory agent in interactions with the FDA.1.20 "Firm Order" means a binding, non-cancelable agreement to purchase Product as evidenced by a purchase order, sales acknowledgement or other evidence to purchase Product in writing and delivered to CytoDyn by American Regent and accepted by CytoDyn in accordance with Section 6.2. 1.21 "First Commercial Sale" means with respect to a Product, the first commercial sale of the Product ...CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More ...CytoDyn is currently enrolling patients in two clinical trials for COVID-19, a Phase 2 randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and a Phase 2b/3 randomized ...Stock analysis for CytoDyn Inc (296:Stuttgart) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Gilead Sciences (NASDAQ: NASDAQ: GILD ), with its $90 billion market capitalization, is a massive player in the anti-viral business. Specifically, in HIV, the company has played an enormous part ...CytoDyn has survived dissident shareholder and board member lawsuits and a board takeover attempt in the past two years. Pourhassan has come under fire for his compensation and management of the ...CytoDyn was Amarex’s largest, most important client. 30. As part of its engagement by CytoDyn, Amarex interfaced directly with, and served as the primary contact for, the FDA for purposes of CytoDyn’s expected BLA submission. Case 8:22-cv-03284-PX Document 1 Filed 12/20/22 Page 6 of 29. 7CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), today announced that it has received a positive response from the U.S. Food and Drug Administration (“FDA”) to conduct a Phase 3, randomized, double blind, placebo controlled trial to evaluate the efficacy and safety of leronlimab in combination with standard of care for ...CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More ...CytoDyn former CEO Nader Pourhassan. February 22, 2022 12:50 PM EST Updated 01:26 PM. FDA+. Coronavirus. Marketing. FDA slams former CytoDyn CEO's misleading interview in new warn ...
296:STU Stuttgart Stock Exchange; 296:MUN Munich Stock Exchange; Cytodyn Inc. Actions. Add to watchlist; Add to portfolio; Add an alert; Price (USD) 0.21; ... Year on year Cytodyn Inc 's net income fell 36.30% from a loss of 154.67m to a larger loss of 210.82m despite revenues that grew -- from 0.00 to 266.00k.. Pensacola weather radar hourly
The forecast for CYDY stock looks positive amid the leronlimab trials. By Mohit Oberoi, CFA. Aug. 13 2021, Published 9:28 a.m. ET. Source: CytoDyn Facebook. There's a proxy war going on between ...However, we also know that the first thing CytoDyn said about this trial was in a press release titled "CytoDyn's Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster ...CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More ...CytoDyn has publicly communicated differences in small subgroups from the CD12 trial (e.g., a sub-group analysis of 62 of the 394 patients studied) suggesting that the data demonstrated a ...CYDY CytoDyn Inc: Germany quotes (Berlin/Stuttgart/Munich): $7,58 = 6,50 Euro! https://wertpapiere.ing.d - #5809269CytoDyn's latest annual report indicates it had a net loss in the fiscal year ended May 31 of $154.6 million, up from $124 million the year before. The company trades over the counter under the ...3 minutes ago. Post #225,872. Re: #225,870: @theswordman - Grape jelly man made a $$ serving on. The jelly man was one of the highest paid board members in the Pacific Northwest when he was on it. I believe he was pulling in around $2M (!!) a year when the average board member in the US makes a median comp of $45K a year. CytoDyn shares dropped more than 17 percent, from $3.81 to $3.15 per share, upon the publication of the WSJ article, the complaint says. According to the lawsuit, this stock drop preceded a September 3 lawsuit filed by the Securities Exchange Commission against Iliad, its principal and several related entities over the alleged purchase of ...Re: sean007 #106787. Sean, I am struggling from my phone to upload Dr Recknor's statement in support of the Cytodyn suit against Amarex. With my mistake this morning in mind, here is the text from Dr Recknor's statement: "Case 8:21-cv-02533-GLS Document 6-3 Filed 10/04/21 Page 1 of 9. IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT ...CytoDyn recently publicized e ncouraging results from their Part 2 open-label portion of the Phase II NASH clinical trial testing 350 mg weekly dose of Leronlimab, demonstrated an average 80 msec ...VANCOUVER, Washington, May 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing... CYDY : 0.1730 (-1.20%) CytoDyn Announces Publication of Peer-Reviewed Paper, "Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in ...CytoDyn has conveyed to investors that their COVID-19 program is a priority for the company, with their last five publicly available investor conference calls in 2020 beginning with a status ...On April 30, 2020, after exercising options to purchase millions of CytoDyn shares at prices less than $1 per share, Pourhassan sold more than 4.8 million shares of CytoDyn stock, 85% of the stock ...CytoDyn trades on the over-the-counter market under the ticker CYDY. Its stock closed Tuesday at 27 cents after news broke of the indictments. It was continuing to fall Wednesday.Stefan Glück, MD, PhD, FRCPC. Dr. Glück is a medical oncologist and was V.P. Global Medical Affairs at Celgene Corporation from October 2014 until December 2019. He oversaw oncology activities worldwide and the Immuno-Oncology program in solid tumors and hematology. He also contributed to Celgene’s activities around the acquisition of early ...... Stuttgart [XSTU], Bolsa Boliviana De Valores [XBOL], Bolsa De Comercio De Buenos ... CytoDyn Inc [296]. Temas: 0, Mensajes: 0. No hay mensajes: 02:00:00: 0.000K ...VANCOUVER, Washington, May 24, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Cyrus Arman, the Company's President, has taken a medical leave of absence.Offers valid only for new residential customers or previous customers with account in good standing who have not had our service within the last 60 days. All names, logos, images and service marks are property of their respective owners. Other restrictions may apply. Check your email online, anytime, anywhere with Webmail.Cytodyn Inc () Stock Market info Recommendations: Buy or sell Cytodyn stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Cytodyn share forecasts, stock quote and buy / sell signals below.According to present data Cytodyn's CYDY shares and potentially its market environment have been in bearish cycle last 12 months (if exists).CytoDyn's mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. The official website for the company is www.cytodyn.com. The biotechnology company can be reached via phone at (360) 980-8524 or via email at [email protected]..
Popular Topics
- Quiltville mystery quilt 2022Zales outlet credit card payment
- Best d3 schoolsFgcu eaccounts
- How to recover venmo account without phone numberRestored republic february 28 2023
- Dimebag darrell crime scene photosCiaran hinds pronunciation
- Http kronos wfc navigator logonDr joe dispenza daughter
- North carolina powerball numbers resultsJing happy hour
- The barn at belamourThe full moon oyster bar jamestown menu